Is claudin-1 a novel target of miR-375 in non-small-cell lung cancer?
CLDN1 is a novel target of miR-375, and high miR-375 expression shortens survival in NSCLC.
The conservative treatment group presented worse audiological tests, regardless of hypertension and diabetes, reinforcing that patients need to undergo a complete hearing assessment for better understanding of the disease and its effects on the auditory system.